<DOC>
	<DOCNO>NCT00894868</DOCNO>
	<brief_summary>This study assess effect vildagliptin leave ventricular function patient type 2 diabetes congestive heart failure ( NYHA Class I-III ) . Effect HbA1c overall safety tolerability also assess .</brief_summary>
	<brief_title>Effect Vildagliptin Left Ventricular Function Patients With Type 2 Diabetes Congestive Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Patients T2DM , diagnose least 3 month prior Visit 1 CHF ( NYHA Class I , Class II , Class III ) Visit 1 LVEF &lt; 40 % Pregnant lactate female FPG ≥ 270 mg/dL ( ≥15 mmol/L )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>CHF , vildagliptin</keyword>
	<keyword>metabolic disease</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>T2DM</keyword>
</DOC>